GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panion & Bf Biotech Inc (TPE:1760) » Definitions » Quality Rank

Panion & Bf Biotech (TPE:1760) Quality Rank


View and export this data going back to 2004. Start your Free Trial

What is Panion & Bf Biotech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Panion & Bf Biotech Quality Rank Related Terms

Thank you for viewing the detailed overview of Panion & Bf Biotech's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Panion & Bf Biotech (TPE:1760) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 16th Floor, F Building, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. It is engaged in research and development of pharmaceuticals and new drugs. It focuses on pharmaceuticals, cosmeceuticals, nutraceuticals, and medical devices sectors. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has two geographic segments Taiwan segment and China, Hong Kong, and Macau segment. It generate majority of the revenue from Taiwan segment.